secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2025-10-16T23:59:59+00:00
Accession:  0001193125-25-240858
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dianthus licenses DNTH212 from Leads Biolabs; $30M upfront, $962M potential milestones
--------------------------------------------------------------------------------

- Up to $38M in upfront and near-term payments ($30M cash plus $8M milestone at Phase 1 start).
- Additional up to $962M in development, regulatory, and sales-based milestones across five indications.
- Tiered royalties from mid-single digits to low double-digit on ex-Greater China net sales.
- Preliminary cash $555M as of Sep 30, 2025; pro forma $525M after $30M payment to Leads.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000119312525240858/0001193125-25-240858-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000119312525240858/dnth-20251016.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-240858

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer